It has been indicated that 20% of the patients with Therapy-Related Myeloid Neoplasms (t-MN) among breast cancer survivors have a germline mutation in the BRCA1/2, CHEK2, TP53, or PALB2 genes, which are important in DNA repair pathways27. The gene discussed is CHEK2; the disease is breast carcinoma.